259 related articles for article (PubMed ID: 1646219)
21. Potency and specificity of CGS-16949A as an aromatase inhibitor.
Santen RJ; Langecker P; Santner SJ; Sikka S; Rajfer J; Swerdloff R
Endocr Res; 1990; 16(1):77-91. PubMed ID: 2139412
[TBL] [Abstract][Full Text] [Related]
22. CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study.
Beretta KR; Hoeffken K; Kvinnsland S; Trunet P; Chaudri HA; Bhatnagar AS; Goldhirsch A; Cavalli F
Ann Oncol; 1990 Nov; 1(6):421-6. PubMed ID: 2150591
[TBL] [Abstract][Full Text] [Related]
23. Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats.
Tominaga T; Yoshida Y; Shimozuma K; Hayashi K; Kosaki G
Eur J Cancer; 1990; 26(5):600-3. PubMed ID: 2144748
[TBL] [Abstract][Full Text] [Related]
24. Novel aromatase inhibitors.
Bhatnagar AS; Häusler A; Schieweck K; Browne LJ; Bowman R; Steele RE
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):363-7. PubMed ID: 2147860
[TBL] [Abstract][Full Text] [Related]
25. The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition.
Kochak GM; Mangat S; Mulagha MT; Entwistle EA; Santen RJ; Lipton A; Demers L
J Clin Endocrinol Metab; 1990 Nov; 71(5):1349-5. PubMed ID: 2146284
[TBL] [Abstract][Full Text] [Related]
26. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
Schieweck K; Bhatnagar AS; Matter A
Cancer Res; 1988 Feb; 48(4):834-8. PubMed ID: 2962734
[TBL] [Abstract][Full Text] [Related]
27. Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A.
Klepp R; Lønning PE; Kvinnsland S
Acta Oncol; 1990; 29(4):469-71. PubMed ID: 2143909
[No Abstract] [Full Text] [Related]
28. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.
Costa LA; Kopreski MS; Demers LM; Chinchilli VM; Santen RJ; Harvey HA; Lipton A
Cancer; 1999 Jan; 85(1):100-3. PubMed ID: 9921980
[TBL] [Abstract][Full Text] [Related]
29. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors.
Häusler A; Schenkel L; Krähenbühl C; Monnet G; Bhatnagar AS
J Steroid Biochem; 1989 Jul; 33(1):125-31. PubMed ID: 2527324
[TBL] [Abstract][Full Text] [Related]
30. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects.
Trunet PF; Mueller P; Bhatnagar AS; Dickes I; Monnet G; White G
J Clin Endocrinol Metab; 1993 Aug; 77(2):319-23. PubMed ID: 8345034
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M
Cancer Res; 1993 Jan; 53(2):266-70. PubMed ID: 8417819
[TBL] [Abstract][Full Text] [Related]
32. Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer.
Dowsett M; Smithers D; Moore J; Trunet PF; Coombes RC; Powles TJ; Rubens R; Smith IE
Eur J Cancer; 1994; 30A(10):1453-8. PubMed ID: 7833101
[TBL] [Abstract][Full Text] [Related]
33. The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.
Demers LM; Lipton A; Harvey HA; Hanagan J; Mulagha M; Santen RJ
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):683-5. PubMed ID: 8386541
[TBL] [Abstract][Full Text] [Related]
34. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
Raats JI; Falkson G; Falkson HC
J Clin Oncol; 1992 Jan; 10(1):111-6. PubMed ID: 1530798
[TBL] [Abstract][Full Text] [Related]
35. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
Miller AA; Lipton A; Henderson IC; Navari R; Mulagha MT; Cooper J
Cancer; 1996 Aug; 78(4):789-93. PubMed ID: 8756373
[TBL] [Abstract][Full Text] [Related]
36. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
[TBL] [Abstract][Full Text] [Related]
37. Effect of the aromatase inhibitor CGS-16949A on pregnancy and secretion of progesterone, estradiol-17beta, prostaglandins E and F2alpha (PGE; PGF2alpha) and pregnancy specific protein B (PSPB) in 90-day ovariectomized pregnant ewes.
Weems YS; Bridges PJ; LeaMaster BR; Sasser RG; Ching L; Weems CW
Prostaglandins Other Lipid Mediat; 2001 Sep; 66(2):77-88. PubMed ID: 11529553
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male.
Bhatnagar AS; Müller P; Schenkel L; Trunet PF; Beh I; Schieweck K
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):437-43. PubMed ID: 1532903
[TBL] [Abstract][Full Text] [Related]
39. Aromatase inhibitor development for treatment of breast cancer.
Masamura S; Adlercreutz H; Harvey H; Lipton A; Demers LM; Santen RJ; Santner SJ
Breast Cancer Res Treat; 1995; 33(1):19-26. PubMed ID: 7749129
[TBL] [Abstract][Full Text] [Related]
40. A comparison of methods measuring aromatase activity in human placenta and rat ovary.
Purba HS; Bhatnagar AS
J Enzyme Inhib; 1990; 4(2):169-78. PubMed ID: 2151521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
